Predictive in silico modeling for hERG channel blockers.

hERG-mediated sudden death as a side effect of non-antiarrhythmic drugs has been receiving increased regulatory attention. Perhaps owing to the unique shape of the ligand-binding site and its hydrophobic character, the hERG channel has been shown to interact with pharmaceuticals of widely varying structure. Several in silico approaches have attempted to predict hERG channel blockade. Some of these approaches are aimed primarily at filtering out potential hERG blockers in the context of virtual libraries, others involve understanding structure-activity relationships governing hERG-drug interactions. This review summarizes the most recent efforts in this emerging field.

[1]  Christopher Miller,et al.  Ion channels: Shake, rattle or roll? , 2004, Nature.

[2]  G. Keserü.  Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.

[3]  Walters Wp,et al.  Guiding molecules towards drug-likeness. , 2002 .

[4]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[5]  Michael J A Walker,et al.  Physicochemical determinants for drug induced blockade of HERG potassium channels: effect of charge and charge shielding. , 2003, Current medicinal chemistry. Cardiovascular and hematological agents.

[6]  Matthew Segall,et al.  In silico prediction of ADME properties: are we making progress? , 2004, Current opinion in drug discovery & development.

[7]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[8]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[9]  S. Ekins.  In silico approaches to predicting drug metabolism, toxicology and beyond. , 2003, Biochemical Society transactions.

[10]  Yu Chen,et al.  Evaluation of Quantitative Structure-Activity Relationship Methods for Large-Scale Prediction of Chemicals Binding to the Estrogen Receptor , 1998, J. Chem. Inf. Comput. Sci..

[11]  Erik Evensen,et al.  A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. , 2002, Journal of medicinal chemistry.

[12]  Gregory W. Kauffman,et al.  Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.

[13]  Sean Ekins,et al.  A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[14]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[15]  Robert Pearlstein,et al.  Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. , 2003, Journal of medicinal chemistry.

[16]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[17]  Menghang Xia,et al.  NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. , 2004, Journal of medicinal chemistry.

[18]  M. Cadene,et al.  X-ray structure of a voltage-dependent K+ channel , 2003, Nature.

[19]  Gisbert Schneider,et al.  A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.

[20]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[21]  M. Sanguinetti,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[23]  William J. Welsh,et al.  Evaluation of Quantitative Structure—Activity Relationship Methods for Large-Scale Prediction of Chemicals Binding to the Estrogen Receptor. , 1998 .

[24]  J. Towbin,et al.  Genotype and severity of long QT syndrome. , 2001, Archives of pathology & laboratory medicine.

[25]  O. Pongs,et al.  Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.

[26]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[27]  Wataru Shimizu,et al.  Cellular mechanisms underlying the long QT syndrome. , 2002, Current opinion in cardiology.

[28]  Christine Williams,et al.  Patch clamping by numbers. , 2004, Drug discovery today.

[29]  M. Sanguinetti,et al.  Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Ekins.  Predicting undesirable drug interactions with promiscuous proteins in silico. , 2004, Drug discovery today.

[31]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[32]  Chris L. Waller,et al.  Prediction of Drug-Like Molecular Properties , 2004 .

[33]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[34]  J. Mitcheson,et al.  Molecular determinants of high-affinity drug binding to HERG channels. , 2003, Current opinion in drug discovery & development.

[35]  R. Young,et al.  Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. , 2003, Journal of medicinal chemistry.

[36]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[37]  Youxing Jiang,et al.  Crystal structure and mechanism of a calcium-gated potassium channel , 2002, Nature.

[38]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[39]  A. Brown,et al.  Drugs, hERG and sudden death. , 2004, Cell calcium.

[40]  Michael Grabe,et al.  Answers and Questions from the KvAP Structures , 2003, Neuron.

[41]  E. Gifford,et al.  Prediction of drug-like molecular properties: modeling cytochrome p450 interactions. , 2004, Methods in molecular biology.

[42]  M. Murcko,et al.  Guiding molecules towards drug-likeness. , 2002, Current opinion in drug discovery & development.

[43]  Brian B. Goldman,et al.  A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.